📋 Tender Overview
The subject of this publication is the conclusion of non-exclusive discount agreements for pharmaceuticals containing the active ingredient Certolizumab pegol (ATC Code according to WHO: L04AB05) under an Open-House model. The contract conclusion is open to all interested pharmaceutical companies during the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations will not be conducted and exclusivity is not granted. The quantity to be purchased is unknown as it depends on demand and the development of the insured population, the prescribing behavior of doctors, and the dispensing and stocking behavior of public pharmacies. Minimum purchase quantities are therefore not guaranteed. Certolizumab pegol
